Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza

PHASE3RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

May 8, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Influenza
Interventions
DRUG

sirolimus and oseltamivir

Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.

DRUG

Oseltamivir

oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.

Trial Locations (1)

Unknown

RECRUITING

Prince of Wales Hospital, Hong Kong

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER